중등증-중증 아토피피부염 소아 환자에서 두필루맙 투여가 피부 증상 및 식품 알레르겐 감작에 미치는 영향

Abstract

Purpose: We aimed to evaluate the effects of dupilumab on the change in skin symptoms and food allergen sensitization in young children with moderate-to-severe atopic dermatitis (AD). Methods: In this retrospective study, we enrolled children aged 6 months to less than 6 years who were diagnosed with moderate-to-severe AD. The dupilumab group received dupilumab treatment, while the control group was treated with topical corticosteroids, topical calcineurin inhibitors, and cyclosporine. We compared age, SCORing Atopic Dermatitis (SCORAD), Eczema Area and Severity Index (EASI), total immunoglobulin E (IgE), and specific IgE against food allergens between the groups and analyzed within-group changes. Results: Data were collected from 20 children in both the dupilumab and control groups. Significant improvements in SCORAD were observed in both groups from 6 months of age to 6 years of age (P<0.001, P=0.001). EASI scores were significantly improved only in the dupilumab group (P<0.001). Significant changes in SCORAD were observed in both groups from 6 months to 23 months of age (the dupilumab group P=0.031; the control group P=0.016). The changes in SCORAD from 2 years to under 6 years of age were significant only in dupilumab group (P<0.001). Both total IgE and specific IgE to egg white, cow’s milk, wheat and peanut significantly decreased in the dupilumab group (P=0.008 and P=0.002, respectively). Conclusion: These findings suggest that dupilumab treatment in young children on moderate-to-severe AD may reduce food allergen sensitization.